Filtered By:
Source: The American Journal of Cardiology
Drug: Aspirin
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 24 results found since Jan 2013.
Meta-Analysis of Cilostazol Versus Aspirin for the Secondary Prevention of Stroke
In conclusion, compared with aspirin, cilostazol is associated with significantly less hemorrhagic stroke, the combined end point of stroke, myocardial infarction, and vascular death, and total hemorrhagic events, with numerically fewer gastrointestinal bleeds when used for the secondary prevention of stroke.
Source: The American Journal of Cardiology - July 8, 2013 Category: Cardiology Authors: James J. DiNicolantonio, Carl J. Lavie, Hassan Fares, Arthur R. Menezes, James H. O'Keefe, Sripal Bangalore, Franz H. Messerli Tags: Miscellaneous Source Type: research
Risk of Stroke in Patients With High On-Clopidogrel Platelet Reactivity to Adenosine Diphosphate After Percutaneous Coronary Intervention
In conclusion, in patients with coronary artery disease undergoing PCI, the presence of HPR to adenosine diphosphate is a risk factor for stroke.
Source: The American Journal of Cardiology - March 17, 2014 Category: Cardiology Authors: Nevio Taglieri, Maria Letizia Bacchi Reggiani, Tullio Palmerini, Gabriele Ghetti, Francesco Saia, Pamela Gallo, Carolina Moretti, Gianni Dall'Ara, Cinzia Marrozzini, Antonio Marzocchi, Claudio Rapezzi Tags: Coronary Artery Disease Source Type: research
Effect of Antiplatelet Therapy (Aspirin + Dipyridamole vs Clopidogrel) on Mortality Outcome in Ischemic Stroke
The optimal regimen of antiplatelet therapy for secondary prevention in noncardioembolic ischemic stroke remains controversial. We aimed to determine which regimen was associated with the greatest reduction in adverse outcomes. We analysed prospectively collected data from the Norfolk and Norwich University Hospital Stroke Register (NNUHSR). The sample population consisted of 3,572 participants (mean age 74.96 ± 12.67) with ischemic stroke, who were consecutively admitted between 2003-2015. Patients were placed on one of three antiplatelet regimens at hospital discharge; aspirin monotherapy, aspirin plus dipyridamole and clopidogrel.
Source: The American Journal of Cardiology - July 2, 2018 Category: Cardiology Authors: Raphae S. Barlas, Yoon K. Loke, Mamas A. Mamas, Joao H Bettencourt-Silva, Isobel Ford, Allan B. Clark, Kristian M. Bowles, Anthony K. Metcalf, John F. Potter, Phyo K. Myint Source Type: research
Effect of Antiplatelet Therapy (Aspirin + Dipyridamole Versus Clopidogrel) on Mortality Outcome in Ischemic Stroke
The optimal regimen of antiplatelet therapy for secondary prevention in noncardioembolic ischemic stroke remains controversial. We aimed to determine which regimen was associated with the greatest reduction in adverse outcomes. We analysed prospectively collected data from the Norfolk and Norwich University Hospital Stroke Register. The sample population consisted of 3,572 participants (mean age 74.96 ± 12.67) with ischemic stroke, who were consecutively admitted between 2003 and 2015. Patients were placed on one of three antiplatelet regimens at hospital discharge; aspirin monotherapy, aspirin plus dipyridamole and clopidogrel.
Source: The American Journal of Cardiology - July 2, 2018 Category: Cardiology Authors: Raphae S. Barlas, Yoon K. Loke, Mamas A. Mamas, Joao H Bettencourt-Silva, Isobel Ford, Allan B. Clark, Kristian M. Bowles, Anthony K. Metcalf, John F. Potter, Phyo K. Myint Source Type: research
Meta-Regression to Identify Patients Deriving the Greatest Benefit from Dual Antiplatelet Therapy After Stroke or Transient Ischemic Attack Without Thrombolytic or Thrombectomy Treatment
The patient's profile drawing the greatest benefit from dual antiplatelet therapy (DAPT) after a non-cardioembolic, ischemic cerebrovascular event is not well characterized. Aim of this meta-regression analysis was to compare DAPT versus single antiplatelet therapy (SAPT) in patients with stroke or transient ischemic attack (TIA). We searched randomized trials evaluating clinical outcome with aspirin plus a P2Y12 inhibitor versus SAPT in patients with non-cardioembolic stroke or TIA. Primary endpoint was the incidence of recurrent stroke; safety outcome measure was major bleeding.
Source: The American Journal of Cardiology - May 24, 2019 Category: Cardiology Authors: Giuseppe Patti, Alessandro Sticchi, Antonio Bisignani, Francesco Pelliccia, Vincenzo Pasceri, Giulio Speciale, Maria Penco Source Type: research
A Novel Model for Prediction of Thromboembolic and Cardiovascular Events in Patients without Atrial Fibrillation
Patients without atrial fibrillation (AF) constitute approximately 75% of patients with thromboembolic events (TE: ischemic stroke, transient ischemic attack (TIA), and systemic embolism)1 but evidence supporting risk stratification and prophylactic treatment in these patients is sparse. The latter may be explained by the lack of an intervention that, beyond treatment of hypertension and cholesterol, reduces TE risk in patients without AF. However, the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial, that almost exclusively included patients without AF, showed that the combination of asp...
Source: The American Journal of Cardiology - June 26, 2020 Category: Cardiology Authors: Kamilla Steensig, Kevin K W Olesen, Morten Madsen, Troels Thim, Lisette Okkels Jensen, Morten W ürtz, Steen Dalby Kristensen, Hans Erik Bøtker, Gregory Y H Lip, John William Eikelboom, Michael Maeng Source Type: research
Prehospitalization Antiplatelet Therapy and Outcomes After Saphenous Vein Graft Intervention
In conclusion, prehospital use of antiplatelet therapy was associated with a lower occurrence of major adverse cardiac events after SVG intervention. We did not find that DAPT improved outcomes compared to single antiplatelet therapy.
Source: The American Journal of Cardiology - October 26, 2012 Category: Cardiology Authors: Ralf E. Harskamp, Marcel A. Beijk, Peter Damman, Jan G. Tijssen, Renato D. Lopes, Robbert J. de Winter Tags: Coronary Artery Disease Source Type: research
Therapy for Triggered Acute Risk Prevention in Subjects at Increased Cardiovascular Risk
In conclusion, it is feasible for those with increased CVD risk to identify potential triggers of acute CVD and to take targeted therapy at the time of these triggers.
Source: The American Journal of Cardiology - April 5, 2013 Category: Cardiology Authors: Geoffrey H. Tofler, Monica Spinaze, Elizabeth Shaw, Thomas Buckley Tags: Preventive Cardiology Source Type: research
Comparison of the Efficacy and Safety of Two Rivaroxaban Doses in Acute Coronary Syndrome (from ATLAS ACS 2–TIMI 51)
In conclusion, the 2 doses of rivaroxaban reduced cardiovascular events in patients with recent acute coronary syndromes treated with antiplatelet therapies; however, the 2.5-mg dose was associated with lower mortality and fewer bleeding complications than the 5-mg dose. Thus, the addition of rivaroxaban 2.5 mg twice daily offers a more favorable balance of efficacy and safety in patients with recent acute coronary syndromes.
Source: The American Journal of Cardiology - May 28, 2013 Category: Cardiology Authors: Jessica L. Mega, Eugene Braunwald, Stephen D. Wiviott, Sabina A. Murphy, Alexei Plotnikov, Nina Gotcheva, Mikhail Ruda, C. Michael Gibson Tags: Coronary Artery Disease Source Type: research
Aspirin for Primary Prevention of Atherothrombotic Vascular Events: How Much “Conclusive” Is “Conclusive?”
Low-dose aspirin has been shown to be effective in preventing atherothrombotic vascular events (nonfatal myocardial infarction, nonfatal stroke, or vascular death) in a meta-analysis including 9 primary prevention trials (50,868 subjects were treated with aspirin and 49,170 received placebo or control). Because meta-analyses aim to identify the effect of an intervention as early as possible, they are usually updated when new trials are published, so that repeated analyses are made on accumulating data. These multiple analyses induce repeated significance testing (usually with p value criterion, α = 5% for a 2-sided tes...
Source: The American Journal of Cardiology - September 3, 2013 Category: Cardiology Authors: Francesco Brigo, Monica Storti, Piergiorgio Lochner, Frediano Tezzon, Raffaele Nardone Tags: Readers' Comments Source Type: research
Meta-Analysis of Randomized Controlled Trials on Risk of Myocardial Infarction from the Use of Oral Direct Thrombin Inhibitors
In conclusion, our data suggest that oral DTIs were associated with increased risk of MI. This increased risk appears to be a class effect of these agents, not a specific phenomenon unique to dabigatran or protective effect of warfarin. These findings support the need for enhanced postmarket surveillance of oral DTIs and other novel agents.
Source: The American Journal of Cardiology - September 27, 2013 Category: Cardiology Authors: Ramin Artang, Eric Rome, Jørn Dalsgaard Nielsen, Humberto J. Vidaillet Tags: Review Source Type: research
Assessment of Dabigatran Utilization and Prescribing Patterns for Atrial Fibrillation in a Physician Group Practice Setting
For years, warfarin and aspirin have been standard therapies for prophylaxis of stroke in atrial fibrillation. In late 2010, dabigatran, an oral direct thrombin inhibitor, became available for use in nonvalvular atrial fibrillation. We sought to evaluate utilization and prescribing patterns of dabigatran in a physician group practice setting. We retrospectively collected prescription data from October 2010 to December 2011 including indication of use, dose, renal function, drug interactions, history of warfarin therapy, and risk assessment scores (CHADS2 and HAS-BLED). Off-label use (history of valve disease or no diagnosi...
Source: The American Journal of Cardiology - November 25, 2013 Category: Cardiology Authors: Blake Carley, Sara Griesbach, Tonja Larson, Kori Krueger Tags: Arrhythmias and Conduction Disturbances Source Type: research
Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial)
In conclusion, most TRACER participants were treated with low-dose ASA, although a high dose was common in North America. High-dose participants tended to have higher rates of ischemic and bleeding outcomes. Although formal statistical testing did not reveal heterogeneity in vorapaxar's effect across dose subgroups, consistent trends support use of low-dose ASA with other antiplatelet therapies.
Source: The American Journal of Cardiology - December 26, 2013 Category: Cardiology Authors: Kenneth W. Mahaffey, Zhen Huang, Lars Wallentin, Robert F. Storey, Lisa K. Jennings, Pierluigi Tricoci, Harvey D. White, Paul W. Armstrong, Philip E. Aylward, David J. Moliterno, Frans Van de Werf, Edmond Chen, Sergio Leonardi, Tyrus Rorick, Claes Held, J Tags: Coronary Artery Disease Source Type: research
Impact of Dual Antiplatelet Therapy on Outcomes Among Aspirin-Resistant Patients Following Coronary Artery Bypass Grafting
This study was designed to define the impact of dual antiplatelet therapy (dAPT) on clinical outcomes among aspirin-resistant patients who underwent coronary artery surgery. We randomly assigned 219 aspirin-resistant patients according to multiple electrode aggregometry to receive clopidogrel (75 mg) plus aspirin (300 mg) or aspirin-monotherapy (300 mg). The primary end point was a composite outcome of all-cause death, nonfatal myocardial infarction, stroke, or cardiovascular hospitalization assessed at 6 months postoperatively. The primary end point occurred in 6% of patients assigned to dAPT and 10% of patients rando...
Source: The American Journal of Cardiology - March 3, 2014 Category: Cardiology Authors: Hrvoje Gasparovic, Mate Petricevic, Tomislav Kopjar, Zeljko Djuric, Lucija Svetina, Bojan Biocina Tags: Coronary Artery Disease Source Type: research
